Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

722 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Among authors: lebwohl m. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle.
Breneman D, Fleischer AB Jr, Abramovits W, Zeichner J, Gold MH, Kirsner RS, Shull TF, Crowe AW, Jaracz E, Hanifin JM; Tacrolimus Ointment Study Group. Breneman D, et al. J Am Acad Dermatol. 2008 Jun;58(6):990-9. doi: 10.1016/j.jaad.2008.02.008. Epub 2008 Mar 21. J Am Acad Dermatol. 2008. PMID: 18359127 Clinical Trial.
Psoriasis Comorbidities and Their Treatment Impact.
Taliercio M, Lebwohl M. Taliercio M, et al. Among authors: lebwohl m. Dermatol Clin. 2024 Jul;42(3):405-416. doi: 10.1016/j.det.2024.02.007. Epub 2024 Mar 13. Dermatol Clin. 2024. PMID: 38796272 Review.
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study.
Pinter A, Soliman AM, Pivneva I, Ghanbariamin R, Yang M, Truong B, Puig L, Lebwohl M. Pinter A, et al. Among authors: lebwohl m. Dermatol Ther (Heidelb). 2024 May;14(5):1259-1271. doi: 10.1007/s13555-024-01164-6. Epub 2024 May 10. Dermatol Ther (Heidelb). 2024. PMID: 38727996 Free PMC article.
Brodalumab: 5-Year US Pharmacovigilance Report.
Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Martin GM, Rawnsley NN, Goehring EL Jr, Jacobson AA. Lebwohl MG, et al. Dermatol Ther (Heidelb). 2024 May;14(5):1349-1357. doi: 10.1007/s13555-024-01162-8. Epub 2024 May 9. Dermatol Ther (Heidelb). 2024. PMID: 38724839 Free PMC article.
722 results